Collaboration will leverage Voro's PrimeBody platform to advance tumor-activated antibody drug conjugates designed to expand therapeutic index and enhance precision targetingSAN DIEGO--(BUSINESS WIRE) ...
In the wake of the recent NAR ruling, which many predict will cause agent commissions to fall by as much as 30%, the Voro model is poised to become an increasingly popular alternative to traditional ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results